Newer clot-buster may offer a safe, effective way to treat ischemic stroke in mobile stroke units

Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) stroke in mobile stroke units, according to real-world experiences detailed in a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2024.

Swiss biotech unloads US rights to Duchenne candidate for $231M

Santhera, a Swiss biotech waiting to see if the FDA will approve its steroid vamorolone for patients with Duchenne muscular dystrophy in the fall, is

June 21, 2023

ITM aims to compete with Novartis after Phase 3 radiopharma win

ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said

January 29, 2025

AMP releases consensus recommendations for CYP3A4 and CYP3A5 genotyping assays

The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of

July 10, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.